Armata Pharmaceuticals reports third quarter loss from operations of $7.8 million
Armata Pharmaceuticals Inc. reported a third-quarter loss from operations of $7.8 million for the period ending September 30, 2025, an improvement from a $9.8 million loss in the same quarter of 2024. The company had $14.8 million in unrestricted cash as of September 30, 2025, up from $9.3 million at the end of 2024. Additionally, positive results from the Phase 2a “diSArm” study of its lead therapeutic phage candidate, AP-SA02, were presented at IDWeek 2025.
Armata Pharmaceuticals Inc. reported a loss from operations of approximately $7.8 million for the third quarter ended September 30, 2025, compared to a loss of approximately $9.8 million for the same period in 2024. As of September 30, 2025, the company held around $14.8 million in unrestricted cash and cash equivalents, up from $9.3 million at the end of 2024. Approximately 36.3 million common shares were outstanding as of November 4, 2025. During the period, Armata highlighted positive results from the Phase 2a “diSArm” study of its lead therapeutic phage candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia, which were presented at IDWeek 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-110351), on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
